We evaluated combinations of CYP17A and 5-α-reductase inhibitors for reducing prostate androgen levels ... Patients were randomly assigned to 3 months of neoadjuvant therapy with (1) goserelin ...

The extent of residual prostate cancer in the surgical specimen following intensified neoadjuvant therapy for high-risk localized prostate cancer may predict metastatic recurrence. Residual ...

in patients receiving salvage prostate bed radiation therapy (sRT) post prostatectomy. Long-term outcomes of a multicenter prospective observational study of active surveillance for early-stage ...

A mainstay of prostate cancer treatment at all stages is a type of hormone therapy called androgen deprivation therapy (ADT). And, newer hormone therapies and combinations with chemotherapy can ...

So the CALGB 90203 study randomly assigned high-risk prostate cancer patients to radical prostatectomy versus neoadjuvant chemohormonal therapy followed by radical prostatectomy. And the ...

On its own, neoadjuvant hormonal therapy can improve tumor control in locally advanced prostate cancer, but studies have shown limited effects on patient survival. The combination of docetaxel ...

Hormonal therapies are effective for recurrent and advanced prostate cancer, with PSA levels crucial for risk stratification. Combination hormone therapy is advised for ... including Lupron ...

I f prostate cancer has spread to other areas of your body, your doctor may recommend androgen deprivation therapy (ADT), which halts the production of androgen hormones, especially testosterone.

Hormonal treatments, called androgen suppression therapy, reduce the amounts or potency of certain hormones to slow the development of prostate cancer. Nonhormonal treatments try to remove or kill ...

An innovative 3D motion management platform for guiding stereotactic body radiation therapy (SBRT) significantly reduced late urinary toxicity in patients treated for prostate cancer compared ...